Study Exposes Bleeding Risk From Pradaxa | Levin Papantonio - Personal Injury Lawyers

Study Exposes Bleeding Risk From Pradaxa

In addition to risks associated with hemorrhaging, a study published in the 9 January 2012 issue of Archives of Internal Medicine reports that patients taking dabigatran have a 33% greater chance of developing heart disease or experiencing cardiac arrest.

Currently, this drug is being investigated by the Food and Drug Administration, though the authors of the above-referenced study continue to insist that for certain patients suffering from arrhythmia, the benefits outweigh the risks.Individual case report may indicate that some of the patients who suffered severe bleeding were unaware of the increased risk.

Learn more about Pradaxa Side Effects